Related Experiment Video

Updated: Jul 30, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K

Beta-Blockers and Hypertension: Some Questions and Answers

Francesco Fici1,2, Nicolas Roberto Robles3, Istemihan Tengiz4

  • 1Department of Cardiovascular Risk, Salamanca University, Salamanca, Spain.

High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
|May 11, 2023
PubMed

Insights

Beta-blockers effectively lower blood pressure and reduce cardiovascular risk, similar to other antihypertensives. Optimal choice depends on patient age and hypertension pathophysiology, with specific types suited for young or elderly individuals.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • International guidelines de-emphasize beta-blockers as first-line hypertension treatment due to older generation drug data.
  • Previous studies suggested lower cardiovascular protection for early beta-blockers compared to other antihypertensives.

Purpose of the Study:

  • To evaluate the efficacy of beta-blockers in hypertension and cardiovascular protection.
  • To compare beta-blocker effects with other antihypertensive agents, particularly in young and elderly populations.

Main Methods:

  • Systematic reviews and meta-analyses were assessed.
  • Effectiveness on blood pressure and cardiovascular outcomes was compared against placebo and other antihypertensive classes.

Main Results:

  • Beta-blockers significantly reduced high blood pressure, comparable to other antihypertensives.
  • Compared to placebo, beta-blockers lowered major cardiovascular event risk.
  • Results comparing beta-blockers to other drug classes were heterogeneous, making global comparisons difficult.

Conclusions:

  • Hypertension pathophysiology differs in young (sympathetic hyperactivity) and elderly (arterial stiffness) patients.
  • Non-vasodilating beta-blockers are recommended first-line for young/middle-aged hypertensive patients.
  • Vasodilating beta-blockers are more suitable for elderly patients due to their hemodynamic profile.
Abstract

Keywords:
Beta-blockersCardiovascular outcomesHypertension

More Related Videos

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

804
Assessing Murine Resistance Artery Function Using Pressure Myography07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

22.3K

Related Concept Videos

Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
773
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
494
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
900
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
530
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
402
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
21